Published by MyelinWatch:
OCTOPUS · OCTOPUS tested metformin and alpha-lipoic acid in progressive MS. After an interim review, the alpha-lipoic acid arm continues to Stage 2 and the metformin arm stops.
OCTOPUS is an adaptive trial platform in progressive MS: it can test several treatment groups against a shared comparison group and change groups as evidence accumulates. Its initial medicines include metformin and alpha-lipoic acid, chosen for possible neuroprotective or repair-related effects; those effects in patients are questions the platform tests.
Approach source: MRC Clinical Trials Unit at UCL — OCTOPUS protocol ↗
OCTOPUS tested metformin and alpha-lipoic acid in progressive MS. After an interim review, the alpha-lipoic acid arm continues to Stage 2 and the metformin arm stops.
Phase 3 study evidence; current human-study status is unknown
The programme is listed as active; current human-study status is unknown.
The trial team reported an interim MRI and clinical signal for alpha-lipoic acid on 17 September 2026. This supports further testing, not a final result on benefit or safety. The metformin arm did not advance.
This is a UK and Australian research study, not an available treatment. UK residents could register interest in Stage 2 at the 17 September announcement; current enrolment and eligibility require direct confirmation. No Greek centre is confirmed. The interim decision does not establish clinical benefit.
The first OCTOPUS review in progressive MS will assess metformin and alpha-lipoic acid. It will look at brain shrinkage on MRI, disability, walking speed and hand function.
Source: OCTOPUS / MRC Clinical Trials Unit at UCL — official trial update ↗
